{"doi":"10.1101/2023.04.06.535927","title":"SARS-CoV-2 Mac1 is required for IFN antagonism and efficient virus replication in mice","abstract":"ABSTRACT Several coronavirus (CoV) encoded proteins are being evaluated as targets for antiviral therapies for COVID-19. Included in this set of proteins is the conserved macrodomain, or Mac1, an ADP-ribosylhydrolase and ADP-ribose binding protein. Utilizing point mutant recombinant viruses, Mac1 was shown to be critical for both murine hepatitis virus (MHV) and severe acute respiratory syndrome (SARS)-CoV virulence. However, as a potential drug target, it is imperative to understand how a complete Mac1 deletion impacts the replication and pathogenesis of different CoVs. To this end, we created recombinant bacterial artificial chromosomes (BACs) containing complete Mac1 deletions (ΔMac1) in MHV, MERS-CoV, and SARS-CoV-2. While we were unable to recover infectious virus from MHV or MERS-CoV ΔMac1 BACs, SARS-CoV-2 ΔMac1 was readily recovered from BAC transfection, indicating a stark difference in the requirement for Mac1 between different CoVs. Furthermore, SARS-CoV-2 ΔMac1 replicated at or near wild-type levels in multiple cell lines susceptible to infection. However, in a mouse model of severe infection, ΔMac1 was quickly cleared causing minimal pathology without any morbidity. ΔMac1 SARS-CoV-2 induced increased levels of interferon (IFN) and interferon-stimulated gene (ISG) expression in cell culture and mice, indicating that Mac1 blocks IFN responses which may contribute to its attenuation. ΔMac1 infection also led to a stark reduction in inflammatory monocytes and neutrophils. These results demonstrate that Mac1 only minimally impacts SARS-CoV-2 replication, unlike MHV and MERS-CoV, but is required for SARS-CoV-2 pathogenesis and is a unique antiviral drug target. SIGNIFICANCE All CoVs, including SARS-CoV-2, encode for a conserved macrodomain (Mac1) that counters host ADP-ribosylation. Prior studies with SARS-CoV-1 and MHV found that Mac1 blocks IFN production and promotes CoV pathogenesis, which has prompted the development of SARS-CoV-2 Mac1 inhibitors. However, development of these compounds into antivirals requires that we understand how SARS-CoV-2 lacking Mac1 replicates and causes disease in vitro and in vivo . Here we found that SARS-CoV-2 containing a complete Mac1 deletion replicates normally in cell culture but induces an elevated IFN response, has reduced viral loads in vivo , and does not cause significant disease in mice. These results will provide a roadmap for testing Mac1 inhibitors, help identify Mac1 functions, and open additional avenues for coronavirus therapies.","journal":"bioRxiv (Cold Spring Harbor Laboratory)","year":2023,"id":390364,"datarank":0.37273599746820013,"base_score":2.4849066497880004,"endowment":2.4849066497880004,"self_citation_contribution":0.37273599746820013,"citation_network_contribution":0.0,"self_endowment_contribution":0.37273599746820013,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":11,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9496,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":448435,"name":"Srivatsan Parthasarathy","orcid":null,"position":1,"is_corresponding":false},{"id":919562,"name":"Roshan Ghimire","orcid":"0000-0002-1397-3966","position":2,"is_corresponding":false},{"id":820312,"name":"Joseph J. O’Connor","orcid":null,"position":3,"is_corresponding":false},{"id":550004,"name":"Catherine M. Kerr","orcid":"0000-0001-7067-3778","position":4,"is_corresponding":false},{"id":962177,"name":"Jessica J. Pfannenstiel","orcid":"0009-0003-0783-3208","position":5,"is_corresponding":false},{"id":1161713,"name":"Debarati Chanda","orcid":"0000-0001-5811-9934","position":6,"is_corresponding":false},{"id":1162133,"name":"Caden A. Miller","orcid":null,"position":7,"is_corresponding":false},{"id":289346,"name":"Robert L. Unckless","orcid":"0000-0001-8586-7137","position":8,"is_corresponding":false},{"id":411048,"name":"Sonia Zúñiga","orcid":"0000-0003-2549-6826","position":9,"is_corresponding":false},{"id":361115,"name":"Luis Enjuanes","orcid":"0000-0002-0854-0226","position":10,"is_corresponding":false},{"id":918330,"name":"Sunil More","orcid":"0000-0001-5007-8795","position":11,"is_corresponding":false},{"id":244495,"name":"Rudragouda Channappanavar","orcid":"0000-0002-7608-1922","position":12,"is_corresponding":false},{"id":109648,"name":"Anthony R. Fehr","orcid":"0000-0003-1560-1573","position":13,"is_corresponding":false},{"id":263067,"name":"Yousef M. Alhammad","orcid":"0000-0001-8435-9042","position":0,"is_corresponding":true}],"reference_count":68,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T01:18:32.854511Z","pmid":"37066301","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}